within Pharmacolibrary.Drugs.ATC.G;

model G03AA11
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.4,
    Cl             = 12 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 0.035 / 1000000,
    adminCount     = 1,
    Vd             = 0.006,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.018333333333333333,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Norgestimate and ethinylestradiol is a combined oral contraceptive containing a progestin (norgestimate) and an estrogen (ethinylestradiol), used for the prevention of pregnancy. It is an FDA-approved and widely used birth control medication in women of reproductive age.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy premenopausal women aged 18-40 years after administration of 0.25 mg norgestimate and 0.035 mg ethinylestradiol orally as a single dose.</p><h4>References</h4><ol><li><p>Song, IH, et al., &amp; Piscitelli, SC (2015). Dolutegravir Has No Effect on the Pharmacokinetics of Oral Contraceptives With Norgestimate and Ethinyl Estradiol. <i>The Annals of pharmacotherapy</i> 49(7) 784–789. DOI:<a href=&quot;https://doi.org/10.1177/1060028015580637&quot;>10.1177/1060028015580637</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25862012/&quot;>https://pubmed.ncbi.nlm.nih.gov/25862012</a></p></li><li><p>Bifano, M, et al., &amp; Bertz, R (2014). Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate. <i>Antiviral therapy</i> 19(5) 511–519. DOI:<a href=&quot;https://doi.org/10.3851/IMP2718&quot;>10.3851/IMP2718</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24343001/&quot;>https://pubmed.ncbi.nlm.nih.gov/24343001</a></p></li><li><p>Schmitt-Hoffmann, AH, et al., &amp; Maares, J (2011). Influence of alitretinoin on the pharmacokinetics of the oral contraceptive ethinyl estradiol/norgestimate. <i>Clinical and experimental dermatology</i> 36 Suppl 2 4–11. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2230.2011.04031.x&quot;>10.1111/j.1365-2230.2011.04031.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21443598/&quot;>https://pubmed.ncbi.nlm.nih.gov/21443598</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end G03AA11;
